<DOC>
	<DOCNO>NCT01583530</DOCNO>
	<brief_summary>The purpose study measure amount belimumab blood give injection skin ( subcutaneously ; SC ) evaluate safety tolerability multiple injection skin healthy subject .</brief_summary>
	<brief_title>Study Belimumab Administered Subcutaneously Healthy Subjects</brief_title>
	<detailed_description>This study design evaluate absolute bioavailability , pharmacokinetics , tolerability , safety single dose ( group 1-4 ) multiple dos ( group 5-6 ) belimumab administer subcutaneously ( SC ) healthy subject .</detailed_description>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Healthy subject define clinically relevant abnormality identify detailed medical history , full physical exam , 12lead electrocardiogram ( ECG ) , clinical laboratory test . Body weight 45 120 kg ( 99 264 lb ) . Must agree use effective contraception throughout study 14 week administration belimumab . Have ability understand requirement study , provide write informed consent , comply study protocol procedure . Key Pregnant nursing . Test positive drug alcohol drug alcohol dependence within past year . Have use prescription medicine within past 30 day herbal/botanical supplement within past 7 day anticipate use study . May use prescription contraceptive , hormone replacement therapy , overthecounter medicine antihistamine nutritional support vitamin , mineral , amino acid . Have receive live vaccine within past 30 day anticipate receipt live vaccine study within 4 month last injection belimumab . Have history allergic anaphylactic reaction drug , food , insect bite sting require medical intervention . Have history allergic reaction contrast agent biological medicine . Have participate clinical trial receive experimental medicine within past 60 day . Have receive treatment B cell target therapy time . Have require management infection within past 14 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Belimumab</keyword>
	<keyword>Injections , Subcutaneous</keyword>
	<keyword>Drug Administration Routes</keyword>
	<keyword>Injections</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Biological Therapy</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Biological Availability</keyword>
</DOC>